ReviewJHEP reports : innovation in hepatology2021
Case-finding strategies in non-alcoholic fatty liver disease.
Review in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Using the enhanced liver fibrosis test to identify disease in at-risk populations.BMJ open gastroenterology · 2026Article
- Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease.The American journal of gastroenterology · 2025Article
- Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Association Between Dietary Inflammatory Index and NAFLD: A Cross-Sectional Study of the National Health and Nutrition Examination Survey.Mediators of inflammation · 2025Article
- Screening for the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Among Patients With Prediabetes and Type 2 Diabetes: A Comparison of Three Screening Systems.International journal of endocrinology · 2025Article
- The association of dietary nutrients consumption with hepatic steatosis and fibrosis from NHANES 2017-2020.Frontiers in nutrition · 2025Article
- Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis.Gastro hep advances · 2025Article
- Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level.Internal and emergency medicine · 2024Article
- The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.International journal of biological sciences · 2024Review
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.Life (Basel, Switzerland) · 2023Review
- Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests.Nature communications · 2023Article
- Should we undertake surveillance for HCC in patients with MAFLD?Therapeutic advances in endocrinology and metabolism · 2023Review
- Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.Cureus · 2022Review
- Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.BMC health services research · 2022Article
- Article
- Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.PloS one · 2022Article
- Association between SII and hepatic steatosis and liver fibrosis: A population-based study.Frontiers in immunology · 2022Article
- Non-alcoholic fatty liver disease: A patient guideline.JHEP reports : innovation in hepatology · 2021Article
- Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the large population of patients with non-alcoholic fatty liver disease (NAFLD), identifying those with advanced disease remains challenging. Many patients are diagnosed late, following the development of liver-related complications, leading to poor clinical outcomes. Accumulating evidence suggests that using non-invasive tests for liver fibrosis in patients with metabolic risk factors improves the detection of patients in need of specialised management and is cost-effective. Because of the vast number of patients requiring evaluation, the active participation of general practitioners and physicians who manage patients with metabolic disorders, such as diabetologists, is crucial; this calls for the increased awareness of NAFLD beyond liver clinics. Non-invasive case-finding strategies will need to be further validated and generalised for upcoming drug therapies to have the required impact on the worldwide burden of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.